TI
BPMC

Turner Investments’s Blueprint Medicines BPMC Stock Holding History

Turner Investments’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,000
Closed -$209K – 27
2017
Q3 		$209K Buy
+3,000
New +$160K 0.95% 50

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Turner Investments's BPMC Position: Q4 2017 in Review

Turner Investments sold out of Blueprint Medicines (BPMC) in Q4 2017, closing a stake of 3,000 shares — an estimated $209K sold.

Turner Investments first reported a position in BPMC in Q3 2017 and held it in 1 quarter. The position peaked at $209K in Q3 2017. 170 funds tracked by Wall St. Rank hold BPMC as of Q4 2017.

  • Turner Investments reported no remaining Blueprint Medicines position as of Q4 2017 after selling out during the quarter.
  • Turner Investments sold 3,000 Blueprint Medicines shares in Q4 2017, an estimated $209K.
  • Turner Investments first reported a position in Blueprint Medicines in Q3 2017 and held it in 1 quarter.
  • Turner Investments's Blueprint Medicines position peaked at $209K in Q3 2017.
  • 170 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2017.

Based on Turner Investments's 13F filing for Q4 2017, filed 2 Feb 2018.